Rosopatamab
Rosopatamab (HuJ591) is a humanized antiPSMA IgG1 monoclonal antibody that can be used in cancer research, especially prostate cancer. Rosopatamab can be linked to the low-energy beta-emitting radioisotope lutetium-177 (177Lu) through the bifunctional chelator DOTA-NHS ester to obtain a radioimmunoconjugate that targets malignant prostate cells with high efficiency[1].
Product Specifications
CAS Number
2260767-49-3
Product Name Alternative
HUJ-591; TLX591
UNSPSC
12352203
Hazard Statement
H302, H315, H319, H335
Target
PSMA; Radionuclide-Drug Conjugates (RDCs)
Type
Inhibitory Antibodies
Related Pathways
Antibody-drug Conjugate/ADC Related; Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/rosopatamab.html
Purity
99.50
Solubility
10 mM in DMSO
Smiles
[Rosopatamab]
Molecular Weight
(144.11 kDa)
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Isoform
RDC Antibody
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
